US FDA declines to approve Aldeyra's eye disease drug
03/04/2025 13:05
April 3 (Reuters) - The U.S. Food and Drug Administration has declined to approve Aldeyra Therapeutics' ALDX.O treatment for dry eye disease, the company said on Thursday. (Reporting by Christy Santhosh in Bengaluru; Editing by Vijay Kishore) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora